BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11244326)

  • 21. Caring for the breast cancer survivor.
    Abdel-Razeq H
    Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
    [No Abstract]   [Full Text] [Related]  

  • 22. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
    J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen and the factor V Leiden mutation.
    Cuzick J
    J Natl Cancer Inst; 2010 Jul; 102(13):918-9. PubMed ID: 20554943
    [No Abstract]   [Full Text] [Related]  

  • 24. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ
    Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen side effects may be attributable to other causes.
    Jones J
    J Natl Cancer Inst; 2001 Jan; 93(1):11-2. PubMed ID: 11136833
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
    Body JJ; Louviaux I; Dumon JC
    Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].
    Wang T; Song ST; Jiang ZF; Bian SG; Wang YJ; Li LQ; Zhu J
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):739-41. PubMed ID: 15733393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biphosphonate therapy in the management of skeletal metastases].
    Grauer A; Ziegler R
    Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parenteral diphosphonates for treating malignant hypercalcemia.
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children.
    Schmid I; Stachel D; Schön C; Bauer M; Haas RJ
    Klin Padiatr; 2001; 213(1):30-4. PubMed ID: 11225473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia.
    Body JJ; Dumon JC; Seraj F; Cleeren A
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1385-8. PubMed ID: 1592885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.
    Llarena NC; Estevez SL; Tucker SL; Jeruss JS
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
    Culbert EC; Schfirin BS
    Obstet Gynecol; 2006 Sep; 108(3 Pt 2):789-91. PubMed ID: 17018504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ; Jones ME;
    J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
    Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
    J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M; Takami H
    Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
    Pecherstorfer M; Schilling T; Blind E; Zimmer-Roth I; Baumgartner G; Ziegler R; Raue F
    J Clin Endocrinol Metab; 1994 May; 78(5):1268-70. PubMed ID: 8175989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.